IMVT
Immunovant Inc

2,166
Mkt Cap
$4.06B
Volume
1.11M
52W High
$29.49
52W Low
$12.72
PE Ratio
-8.19
IMVT Fundamentals
Price
$22.79
Prev Close
$23.16
Open
$23.62
50D MA
$19.11
Beta
0.97
Avg. Volume
1.89M
EPS (Annual)
-$2.73
P/B
7.78
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Immunovant (NASDAQ:IMVT) Shares Up 8.2% - Time to Buy?
Immunovant (NASDAQ:IMVT) Stock Price Up 8.2% - Here's Why...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Quinn Opportunity Partners LLC Acquires 16,008 Shares of Immunovant, Inc. $IMVT
Quinn Opportunity Partners LLC raised its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 45.6% in the second quarter, according to the company in its most recent filing with the...
MarketBeat·6d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Has $7.18 Million Holdings in Immunovant, Inc. $IMVT
Connor Clark & Lunn Investment Management Ltd. raised its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 23.1% during the 2nd quarter, according to its most recent filing with the...
MarketBeat·7d ago
News Placeholder
Immunovant (NASDAQ:IMVT) Shares Down 6.8% - Here's What Happened
Immunovant (NASDAQ:IMVT) Trading Down 6.8% - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Zacks·9d ago
News Placeholder
Immunovant (NASDAQ:IMVT) Issues Earnings Results, Misses Expectations By $0.01 EPS
Immunovant (NASDAQ:IMVT - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of...
MarketBeat·9d ago
News Placeholder
Insights into Immunovant's Upcoming Earnings
read more...
Benzinga·13d ago
News Placeholder
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Zacks·3mo ago
News Placeholder
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
Zacks·3mo ago

Latest IMVT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.